Shanghai Sanyou Medical (SHA:688085) established a biotechnology joint venture in partnership with South Korean counterpart CGBio, according to a Shanghai Stock Exchange filing on Friday.
The venture, Litian (Taicang) Biotechnology, has a registered capital of 60 million yuan and will develop regenerative medicine, such as innovative cellular biomaterials.
The Chinese orthopedic products manufacturer invested 39.6 million yuan, owning 66% of the venture, and CGBio injected 20.4 million yuan, holding the venture's remaining 34%.
Sanyou's shares closed less than 2% higher.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。